UNSPSC 51373471: Hydrocodone/pheniramine/phenylephrine/phenylpropanolamine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373471 Hydrocodone/pheniramine/phenylephrine/phenylpropanolamine/pyrilamine is a Commodity code that does not align with the state and local procurement activity currently tagged under it. The recent opportunities posted under this code involve parenteral pharmaceutical products and naloxone procurement, not the specific combination-drug formulation the code nominally describes. The Washington State Department of Corrections RFQ (RFQQK13020) solicits parenteral nutrition solutions, intravenous solutions, and controlled substances for incarcerated individuals, requiring documented experience preparing and delivering IV solutions with 24-hour turnaround on TPN and PPN bags. The Seminole County, Florida IFB (IFB60459723LAS) seeks naloxone units and drug deactivation systems for community health initiatives. While both opportunities involve pharmaceuticals delivered to state and local entities, neither matches the narrow scope of the code's stated commodity.

State and local issuing bodies tagging opportunities to this code include a state department of corrections and a county health procurement office, spanning Washington and Florida. The Washington opportunity emphasizes minority and women-owned business participation goals and sets fixed pricing through a two-year initial term with deliveries across eight facilities in three regional zones. The Seminole County procurement calls for 1,900 naloxone units and 800 deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The code shows limited and geographically dispersed recent activity, and the mismatch between the code's nominal pharmaceutical formulation and the parenteral and naloxone products actually being procured suggests either tagging errors or a code classification that does not reflect current state and local purchasing patterns in this category.